



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

TO: Primary Clinical Research Associates

FROM: Janis Wobschall
Protocol Development Coordinator

DATE: October 4, 2006

SUBJECT: N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The following forms have been updated:

Evaluation/Treatment Form – broken down into 3 forms: one indicating Cycles 1 and **3**; one indicating **Evaluation Form For End of 4-6 Week Rest Period**; one that indicates **Cycles 4 through 8**

All Patients/Active Monitoring/Blood Specimen Submission Form - indicates Day **8** rather than Day 7 for the time point collections

MTD/Active Monitoring/Blood Specimen Submission Form – indicates Day **8** rather than Day 7 for the time point collections